Immunotherapies are designed to empower the body’s own immune cells to recognize and destroy cancer cells. However, many patients respond poorly to these treatments. One major reason is that immune cells often fail to enter tumors in sufficient numbers. A research team led by Hellmut Augustin of DKFZ and Heidelberg University therefore set out to investigate the role of tumor blood vessels in this process.
Blood vessels guide immune cells
The researchers focused on liver metastases, which commonly occur in advanced cancer and are often difficult to treat with immunotherapy. Within the blood vessels of metastases, the team identified a specialized subgroup of endothelial cells, the cells lining the inside of blood vessels. These cells produce lipoprotein lipase (LPL), a key enzyme involved in fat metabolism. The LPL-producing endothelial cells act like guides for activated T cells, the immune cells capable of specifically attacking cancer cells. The more LPL-producing endothelial cells were present, the more T cells were able to enter the tumor and fight cancer cells.
Blood vessel cells display a “wanted poster” of the tumor
The researchers discovered that these LPL-rich endothelial cells can present tumor-derived components on their surface, a process known as antigen presentation. This function is normally performed by specialized immune cells. The team has now shown that LPL also enables this specific subgroup of endothelial cells within tumors to perform this task. Endothelial cells display a molecular “wanted poster” of the tumor to passing T cells, alerting them to the presence of cancer cells. As a result, T cells can more readily recognize where tumor tissue is located and migrate from the bloodstream into the tumor, where they can exert their cancer-fighting functions.
“Blood vessels are not merely passive pipelines supplying blood to tumors. They actively instruct the immune system and help T cells recognize and attack metastatic cancer cells,” says Xiaowen Zhang, first author of the study.
LPL improves tumor control
In several experimental mouse models of melanoma metastasis in the liver, the researchers found that increasing LPL levels in endothelial cells allowed more T cells to enter the metastases, leading to stronger tumor regression. Conversely, when LPL was switched off, the immune response was significantly weaker.
This discovery opens new perspectives for cancer immunotherapy. In particular, for so-called “immunologically cold” tumors, which espond poorly to immunotherapy, targeted activation of this mechanism may help in the future to recruit more immune cells into tumors.
Evidence of clinical relevance
Analyses of human liver metastases from different tumor types confirmed the clinical relevance of the findings: tumors with high numbers of LPL-positive blood vessels also showed increased infiltration by T cells.
“We have uncovered a surprising new mechanism by which the vascular system regulates anti-tumor immunity,” explains study leader Hellmut Augustin. Co-study leader Mahak Singhal adds: “In many metastatic tumors, T cells fail to gain access to tumor tissue. Our findings suggest that targeted reprogramming of tumor blood vessels could help make such therapy-resistant tumors responsive to immunotherapy.”
Publication :
Xiaowen Zhang, Miki Kamiyama, Margaret Tulessin, Lorna Rinck, Jan-Philipp Mallm, Michael Kilian, Dennis A. Agardy, Mathias Heikenwälder, Michael Platten, Carolin Mogler, Mahak Singhal, Hellmut G. Augustin: LPL-positive endothelial cells control T cell homing in liver metastasis.
Cancer Discovery 2026, DOI: https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-25-1411
A picture is available for download:
https://www.dkfz.de/fileadmin/user_upload/Skoe/Pressemitteilungen/2026/Picture-CD-press-release.png
Picture Caption : Intratumoral blood vessels of a liver metastasis are stained in blue, T cells in green.
Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: “Source: Augustin/DKFZ”.
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ’s Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse@dkfz.de). Any commercial use is prohibited.
With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.
To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:
National Center for Tumor Diseases (NCT, 6 sites)
German Cancer Consortium (DKTK, 8 sites)
Hopp Children's Cancer Center (KiTZ) Heidelberg
Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Research, Technology and Space and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.
Cancer Discovery